However, in contrast to antigen presentation via MHC class I, prominently via (cancer) epithelial cells, that activate tumor cytotoxic CD8+ T cells, MHCII presentation in the TME usually activates CD4+ Treg that actively suppress cancer immunity [9,10,11,12]. The gene discussed is CD8A; the disease is neoplasm.